Hims & Hers FDA Surge: $2.2B Peptide Market Opens for Telehealth
Will the FDA's surprising peptide decision turn Hims & Hers into a multi-billion-dollar powerhouse, or is Wall Street right to stay cautious?
Hims & Hers Health Forecast Jumps 8% on Analyst Upgrades
Can analyst optimism outweigh FDA peptide uncertainty in the Hims & Hers Health Forecast after an 8% stock surge?
Hims & Hers peptide regulation: +10.5% rally tests FDA bet
Is the latest FDA shift on peptides turning Hims & Hers into a long-term growth story or just fueling a speculative spike?